Corporate Reputation of Pharma Survey 2022

The 2022 Corporate Reputation of Pharma report is now available!

Based on the feedback of over 2200 patient groups worldwide, this report provides invaluable insights into how pharma companies are perceived by patient groups and how they can improve.


The global edition of the report is now available. Read the press release here or request a copy of the full report using the contact form below:

    PatientView has been conducting its annual ‘Corporate Reputation of Pharma’ survey for 12 years. Each year, thousands of health campaigners share their perspectives on how individual pharma companies and the industry as a whole performed during the last 12 months.

    In 2022, we achieved 2,200+ survey responses from patient groups across the world.

    Few studies explore the opinions of patient groups worldwide on whether pharma meets their expectations (and, if not, how might the industry, and individual pharma companies, improve). This survey gives health campaigners and patient-advocacy groups an opportunity to comment on the pharma industry’s performance, and a platform to raise important issues in patient care.

    Patient groups are uniquely positioned to share valuable insights, as they network with all other stakeholders in the healthcare system. In 2022, PatientView collected responses from patient groups across 27 different speciality disease areas for insights across the healthcare sector.




    PatientView has also collected the number of patient-group respondents which were familiar with and had worked with each of the 42 companies reviewed in the survey.

    The global report will be published on Friday 28th April 2023.

    What patient groups told us about 2022…



    Explore more of PatientView’s research.